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Objective: Solifenacin is an anticholinergic agent selective to M3 cholinergic recep-
tor and has been widely used to treat overactive bladder (OAB). In this study, the 
efficacy and safety of solifenacin in patients with OAB were evaluated.
Materials and Methods: A prospective study for evaluating the therapeutic results 
of solifenacin in patients with “OAB dry” (OAB without urge incontinence) or “OAB 
wet” (OAB with urge incontinence) was performed. Solifenacin 5 mg daily was given 
and the endpoint was set at the 6th month to evaluate the changes in urgency 
severity score (USS) after treatment. The measured parameters, including urinary 
frequency, nocturia, USS, maximum flow rate (Qmax), voided volume, post-voiding 
residual volume (PVR) and functional bladder capacity (FBC), were recorded at every 
visit. Patients were further categorized into OAB wet (USS, 4) and OAB dry (USS, 1, 2 
and 3), and the effect and adverse events of solifenacin treatment were analyzed.
Results: A total of 54 patients was enrolled in this study and completed all follow-up 
visits. Significant improvements of USS, daytime urinary frequency and nocturia 
were noted in both OAB dry and OAB wet groups. The urinary frequency and noctu-
ria episodes also improved significantly after taking solifenacin. Mean USS improved 
from 3.28 ± 0.94 to 2.02 ± 1.62 (p < 0.001), and Qmax increased significantly from 
13.9 ± 8.9 mL/s to 15.8 ± 9.6 mL/s (p = 0.04) at baseline and 6 months, respectively. 
FBC and voiding volume were also found to have significant improvement; however, 
no significant change in PVR was noted from baseline to endpoint. The therapeutic 
efficacy showed no significant difference between the OAB dry and OAB wet groups. 
Minor adverse effects were noted in only seven patients (13.0%), and the most com-
mon complaint was difficult urination (5.6%).
Conclusion: This study demonstrated that solifenacin is an effective antimuscarinic 
for treatment of OAB with few adverse effects. Patients with either OAB wet or OAB dry 
can benefit from solifenacin treatment, in terms of improvement in USS, frequency, 
nocturia episodes and bladder capacity, without compromising voiding efficiency. 
Only 13.0% of patients had minor adverse effect, typically dysuria.
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1. Introduction
Overactive bladder (OAB) is a condition characterized by 
symptoms of frequency, urgency, with or without urge 
incontinence.1 OAB was estimated to occur in 12–17% 
of the population in Europe and USA, and the prevalence 
of OAB tends to increase with increasing age.2,3
It was generally accepted that antimuscarinics are 
the first choice in the treatment of OAB.4 Muscarinic re-
ceptors are identified to locate at the urothelium as well 
as detrusor muscle.5–7 Among several antimuscarinics, 
the affinity of solifenacin to M3 receptor was greater 
than those of oxybutynin and tolterodine.8,9
Patients with “OAB dry” (OAB without urge inconti-
nence) and “OAB wet” (OAB with urge incontinence) 
have different clinical presentations. OAB dry has been con-
sidered as hypersensitive bladder, which is likely to cause 
by urothelial dysfunction or overexpression of sensory re-
ceptors in the urothelium. On the other hand, OAB wet 
might be a condition of detrusor dysfunction involving sev-
eral possible mechanisms from detrusor to central nerve 
system, and the true mechanism of OAB has not been 
completely elucidated.10 Yamaguchi et al.11 defined OAB 
as a hypersensitivity disorder, because most patients could 
not differentiate urge to void from urgency exactly.11
Although several studies have revealed good therapeu-
tic effect of solifenacin in treating OAB compared with 
other antimuscarinics,12–16 only few studies have men-
tioned the efficacy of solifenacin in OAB dry and OAB 
wet.17 This study was designed to compare the efficacy 
and adverse effects of solifenacin treatment in OAB wet 
and OAB dry.
2. Material and Methods
This is a prospective study. Patients older than 18 years 
from either sex presenting with urinary frequency, or 
urgency with or without urge incontinence were eligible 
for recruitment. Exclusion criteria included active urinary 
tract infection, urinary retention, detrusor underactivity 
proven by urodynamic study, post-voiding residual vol-
ume (PVR) > 150 mL, and patients with severe chronic 
systemic disease. Solifenacin 5 mg once daily orally was 
prescribed to patients without escalating the dose dur-
ing the treatment period. All patients were followed up 
at 1 week, and 1, 3 and 6 months after treatment.
The primary endpoint was change in the urinary ur-
gency severity score (USS; reported as 0 to 4, representing 
none, mild, moderate severe urgency to urge inconti-
nence) from baseline to 6 months after starting solif-
enacin treatment. The secondary endpoints measured 
the parameters, which included voiding frequency at 
daytime and nighttime, maximum flow rate (Qmax), void-
ing volume, functional bladder capacity (FBC), and PVR. 
USS and adverse events were evaluated by the same 
investigator during follow-up. The patients were further 
categorized based on USS into the OAB dry (USS, 1, 2 
and 3) and OAB wet (USS, 4) groups.
Statistical analysis was performed by multiple meas-
urement test and paired t test for consecutive parameters. 
A p value of < 0.05 was considered statistically significant. 
The common adverse events of antimuscarinics, such as 
difficult urination, dry mouth, constipation, blurred vision, 
dizziness and dry eye, were also recorded at each visit.
3. Results
A total of 125 patients were enrolled in this study, and 
54 patients, including 11 women and 43 men, completed 
the study and were followed up at all time-points. The 
remaining 71 patients were not enrolled in this study, 
and they included 58 patients who did not return for 
follow-up (of whom 22 patients had improved lower uri-
nary tract symptoms [LUTS] and 36 did not have), 11 
patients who were still on treatment, and two patients 
who switched to other medications due to unimproved 
LUTS, were not enrolled in this study. No adverse effects 
were noted in the chart recording of these 71 patients. 
Twenty-five patients were categorized as having OAB dry 
(OAB dry group) and 29 as having OAB wet (OAB wet 
group). There was no significant difference in the mean 
age between the OAB dry and OAB wet groups.
As shown in Table 1, the USS, daytime frequency 
and nocturia improved significantly from baseline to 6 
months after solifenacin treatment. Qmax was also 
noted to increase significantly in the patients overall and 
in the OAB wet group but not OAB dry group (p = 0.03). 
The voided volume and FBC increased significantly (all 
p = 0.05), but PVR did not increase at 6 months either in 
the OAB dry or OAB wet group. Figure 1 shows the changes 
in USS and Qmax, and Figure 2 shows the changes in 
voided volume, PVR and FBC at all time-points from base-
line to 6 months. The changes in USS and voiding param-
eters improved gradually from baseline to 1 month and 
became stably improved after 3 months’ treatment.
Figure 3 shows the differences in the measured pa-
rameters between OAB dry and OAB wet groups. There 
were no significant differences in all parameters between 
these two groups. The mean USS decreased by 46% and 
34% in the OAB dry and OAB wet groups, respectively. 
The mean daytime frequency and nocturia decreased, 
and the voided volume and FBC increased in both OAB 
dry and OAB wet groups at 6 months.
After treatment with solifenacin for 6 months, the USS 
decreased by at least 1 scale point in 12 patients with OAB 
dry (48%; i.e., 20% by 3 scale points, 24% by 2 scale points, 
and 4% by 1 scale point) and 13 with OAB wet (44.8%; i.e., 
20.7% by 4 scale points, 13.8% by 3 scale points, 3.4% by 
2 scale points, and 6.9% by 1 scale point). Based on the 
change in primary end-point, there was no significant 
difference in therapeutic efficacy between the OAB wet 
and OAB dry groups (p = 0.54).
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The adverse events at all time-points are listed in 
Table 2. The incidence of adverse events did not increase 
from 3 months to 6 months after treatment. At 6 months, 
only seven patients (13.0%) complained of any adverse 
effect. Difficult urination was the most common com-
plaint (three of 54 patients, 5.6%). Other adverse events, 
including dry mouth, constipation, dizziness and gas-
trointestinal upset, occurred in one patient each (1.9%).
4. Discussion
This study demonstrated that solifenacin is effective in 
treatment of patients with OAB. There was no difference 
in therapeutic efficacy between the OAB wet and OAB 
dry groups. The USS, daytime frequency and nocturia 
improved significantly after treatment. Voided volume 
and FBC were also noted to have significant improve-
ment without affecting voiding efficacy. The results of 
this study is consistent with previous reports.15,17–19
Solifenacin is considered to be a better antimuscarinic 
agent than other antimuscarinics because of its higher 
affinity to M2 and M3 muscarinic receptors, which might 
play a major role in bladder contractility.9 One previous 
study has shown that the mean frequency of micturition 
decreased by 21% and 19.5% in patients receiving tol-
terodine and oxybutynin, respectively, for 12 weeks.20 
The results of this study confirmed the same therapeutic 
Table 1 Comparison of the changes in parameters between OAB-dry and OAB-wet subgroups*
 Total (n = 54) OAB dry (n = 25) OAB wet (n = 29)
 Baseline 6 months Baseline 6 months Baseline 6 months
USS 3.28 ± 0.94 2.02 ± 1.62† 2.44 ± 0.77 1.32 ± 1.18† 4.00 ± 0.00 2.62 ± 1.72†
Daytime frequency 7.44 ± 3.60 5.80 ± 1.98† 7.84 ± 3.51 6.16 ± 2.91† 7.10 ± 3.70 5.48 ± 2.03†
Nocturia 4.40 ± 2.77 2.70 ± 1.24† 3.92 ± 1.91 2.80 ± 1.26† 4.14 ± 3.37 2.62 ± 1.24†
Qmax (mL/s) 13.9 ± 8.9 15.8 ± 9.6† 14.0 ± 8.4 15.6 ± 8.9 13.7 ± 9.4 15.9 ± 10.4†
PVR (mL) 52.9 ± 45.1 64.9 ± 73.4 47.0 ± 43.2 51.7 ± 65.4 58.1 ± 46.9 76.2 ± 81.2
Voided volume (mL) 204 ± 137 257 ± 165† 229 ± 151 298 ± 203† 182 ± 122 222 ± 117†
FBC (mL) 257 ± 149 325 ± 190† 276 ± 172 350 ± 245† 240 ± 126 304 ± 128†
*Data are presented as mean ± standard deviation; †p < 0.05 compared with the baseline data. OAB = overactive bladder; USS = urgency severity 
score; Qmax = maximum flow rate; PVR = post-voiding residual volume; FBC = functional bladder capacity.
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Figure 1 The changes in (A) urgency severity score (USS) and (B) maximum flow rate (Qmax) during follow-up period.
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Figure 2 Changes in post-voiding residual volume (PVR), voided volume and functional bladder capacity (FBC) in (A) overactive 
bladder (OAB) dry group and (B) OAB wet group during all follow-up time-points.
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effects of solifenacin in both OAB dry and OAB wet 
patients.
Muscarinic receptors have been found to be located 
on the bladder urothelium and suburothelium structure 
in addition to the detrusor muscles.21,22 The binding of 
antimuscarinics to receptors on the detrusor muscles 
and the binding of the metabolite of antimuscarinics 
excreted in urine to the receptors on the urothelium 
play an important role in treating OAB.23,24 The expres-
sion of muscarinic receptors, typically the M2 and M3 
subtypes, on the bladder urothelium and detrusor 
muscle has been found to increase in rats with bladder 
outlet obstruction and metabolic syndrome, the condi-
tions of both of which might predispose to detrusor 
overactivity.25–27
Solifenacin is a highly lipophilic agent, is completely 
oral bioavailable, and is metabolized by the cytochrome 
P450 3A isozyme. Fifty percent of the oral dose of solif-
enacin will be eliminated renally as the parent compound, 
which is higher than that of darifenacin and tolterod-
ine.28 A recent report also revealed that when the solif-
enacin is metabolized and excreted in human urine, its 
metabolite provides a better pharmacologic advantage 
for treating detrusor overactivity in rats than tolterodine 
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Figure 3 Therapeutic effects on frequency, urgency symptoms and void-
ing parameters between overactive bladder (OAB) dry and OAB wet groups. 
(A) Changes in parameters of urgency severity score (USS), daytime fre-
quency and nocturia, (B) changes in parameters of functional bladder 
capacity (FBC), post-voiding residual volume (PVR) and voiding volume, and 
(C) changes in maximum flow rate (Qmax) from baseline to 6 months.
Y.C. Chen, et al
42 Vol. 21, 38–43, March 2010
or darifenacin.29 The result of this study showed no sig-
nificant difference between OAB dry and OAB wet, 
which might be explained by the high affinity of solif-
enacin on muscarinic receptors on the urothelium and 
detrusor muscles and a higher metabolite concentration 
of the parent compound of solifenacin in urine.
This study also revealed that the change in USS de-
creased gradually with time and became stably decreased 
after 3 months’ treatment. The treatment course of an-
timuscarinics on OAB needs at least 3 months to reach a 
plateau. It is because the therapeutic effect of antimus-
carinics is not only attributed to direct receptor blocking 
effects but also influenced by the drug concentration 
reaching to a maximal steady state. Solifenacin needs at 
least 2–3 months to reach a maximal stable therapeutic 
effect as for other types of antimuscarinics.9 In our study, 
only 48% of the patients with OAB dry and 45% with 
OAB wet had USS decreased by at least 1 scale point at 
6 months, suggesting that the dose of solifenacin should 
be escalated if the maximal effect is not reached after 
3 months of treatment. Therefore, if there is no signifi-
cant improvement after taking solifenacin for an initial 
3 months, increasing the dosage to 10 mg daily could be 
considered.15,18,19,30
Concerning the adverse effects of solifenacin, only 
minor adverse events occurred in 13.0% of the patients 
overall at 6 months after treatment, indicating that solif-
enacin at a dosage of 5 mg daily is safe for treating pa-
tients with OAB. An incidence of adverse effects of less 
than 15% was noted during the follow-up period, and 
this result was better than in other previous reports, in 
which the incidences of dry mouth and constipation 
were reported to be 21.4% and 13.3%, respectively, after 
solifenacin treatment.18 We found fewer adverse effects 
occurring in this study in comparison with a 25% discon-
tinuation rate in patients treated with oxybutynin in an-
other study.30 The fewer adverse effects in this study may 
be due to the following: (1) the small sample size of 54 pa-
tients would introduce bias; (2) patients took solifenacin 
5 mg orally per day, and the lower dosage of solifenacin 
would cause minor adverse effects; and (3) as patients 
who sought help often focused on their LUTS, and once 
the LUTS improved, the tolerable adverse effects might 
be ignored.
In conclusion, patients with either OAB wet or OAB 
dry can benefit from solifenacin treatment, in terms of 
improvement in USS, frequency and nocturia episodes, 
and bladder capacity without compromising voiding 
efficiency. Only 13% of the patients had minor adverse 
effects, typically dysuria.
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